에 대한 최신 뉴스 TransMedics Gr (NASDAQ:TMDX) 주식

TransMedics Gr

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

TransMedics Group

Earnings

News

Guidance

Health Care

After-Hours Center

Movers

TMDX

트랜스메딕스 그룹(NASDAQ:TMDX) 주식은 회사가 예상보다 저조한 2024년 3분기 재무 결과를 발표한 후 월요일 애프터 마켓에서 22% 이상 급락했다.

트랜스메딕스 그룹의 주식은 부진한 3분기 실적으로 시간외 거래에서 22% 이상 급락

TransMedics Group Inc

The cryptocurrency market is experiencing a surge of optimism following signals of a <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43008666/sec-under-trump-administration-to-revise-crypto-policies-report">pro-crypto policy</a> shift from the incoming administration under President-elect Donald Trump.
<h2 class="wp-block-heading">Industry Cheers Pro-Crypto Pivot&#8230;</h2>
Key figures and investors in the crypto space have expressed relief at the anticipated policy change, buoyed by appointments of crypto-friendly individuals to prominent positions, including David Sacks as AI and crypto czar, and Paul Atkins as the nominee for SEC Chair.
These moves, coupled with expectations of executive orders designed to establish a Bitcoin reserve, <a href="https://nypost.com/2025/01/16/business/new-trump-ends-crypto-communitys-government-harassment/">according</a> to New York Post and halt debanking practices, signal a new era for the industry in the US.
Frank Chaparro, an early Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) investor, emphasized the magnitude of this shift, describing it as &#8220;a seismic change in the approach and tone of the government.&#8221;
He added that banks, which were previously discouraged from working with crypto firms, are expected to become active participants in the sector. 
Previously, many startups, facing regulatory hurdles and financial barriers, were forced to move their operations outside of the US. Now, this trend is expected to reverse with firms looking to move back, or expand into the US market. 
The overall mood within the crypto industry is one of optimism, as many anticipate a period of growth and innovation.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43032961/decentralized-finance-will-reshape-the-internet-crypto-founder-says">Decentralized Finance Will Reshape The Internet, Crypto Founder Says</a>
<h2 class="wp-block-heading">&#8230;But Not Everyone Agrees</h2>
However, with this enthusiasm comes debate regarding specific proposals, such as the nature of the proposed <a href="https://www.benzinga.com/25/01/43021074/oklahoma-joins-growing-list-of-states-proposing-bitcoin-as-strategic-reserve-asset">strategic reserve</a> and what kind of digital assets it would prioritize.
While there is a general consensus that the change in administration will improve the crypto space in the U.S., there are some varied views on how the implementation should work.
Many are anticipating the forthcoming executive orders and the details it will contain, as this will provide clarity on many of the questions being raised in the market. 
The market is also witnessing events such as the upcoming Crypto Ball in Washington D.C. which will be sponsored by key figures in the crypto space, which underscores the anticipation of a positive future for the crypto industry.
Alexander Grieve, VP of Government Affairs at Paradigm, <a href="https://x.com/AlexanderGrieve/status/1879871039108153404">cautioned</a> against taking press narratives at face value, urging stakeholders to wait for official communication directly from the President and his staff before making assumptions.
David Bailey, CEO at Bitcoin Magazine, also <a href="https://x.com/DavidFBailey/status/1879851786166771868">expressed</a> skepticism, particularly regarding proposals to favor U.S.-based digital assets. 
<h2 class="wp-block-heading">Strategic Bitcoin Reserve Interest On The Rise</h2>
Hunter Horsley, CEO of Bitwise, <a href="https://x.com/HHorsley/status/1879679937415954680">highlighted</a> the growing institutional interest in Bitcoin, saying that, "Nation-states are now asking about Bitcoin ETFs and considering shifting foreign reserves into BTC." 
Meanwhile, Senator Cynthia Lummis has <a href="https://x.com/Cointelegraph/status/1879914116648939746">raised</a> concerns about the U.S. Marshals Service&#8217;s plans to sell nearly 70,000 Bitcoin that were previously seized.
She has formally requested detailed information about this planned sale, citing potential losses and questioning the wisdom of liquidating such assets given the new administration&#8217;s pro-crypto stance. 
Her letter raises concerns about transparency, decision-making processes and long-term strategic planning regarding these Bitcoin holdings.
Read Next: 
<ul>
<li><a style="font-weight: bold;" href="https://www.benzinga.com/markets/cryptocurrency/25/01/43028215/coinbase-launches-bitcoin-backed-loans-for-us-users">Coinbase Launches Bitcoin-Backed Loans For US Users</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Donald Trump Reportedly Open To US Crypto Reserve As Bitcoin Reserve Chatter Gathers Steam

Goldman Sachs analyst Kash Rangan maintains BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) with a Neutral and lowers the price target from $35 to $31.

Price Target

Analyst Ratings

Goldman Sachs Maintains Neutral on BorgWarner, Lowers Price Target to $31

Diamond jewelry retailer Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) is the subject of a new short report that comes as shares trade near 52-week lows after the company lowered <a href="https://www.benzinga.com/25/01/42975858/signet-jewelers-slashes-q4-sales-forecast-stock-drops-over-16">fourth-quarter guidance.</a>
Here's why The Bear Cave predicts more trouble ahead.
Signet's Increased Competition: The latest <a href="https://www.benzinga.com/topic/the-bear-cave">Bear Cave short report</a> targets the diamond jewelry company on the thesis that lab grown diamonds will continue to cut into Signet's market share.
"The Bear Cave believes today's youth and future generations will shift towards lab-grown diamond engagement rings and mined diamonds will be a vestige of the past," the <a href="https://thebearcave.substack.com/p/problems-at-signet-jewelers-sig">report </a>said.
Benzinga contacted Signet for comment on the report. 
Signet operates the Zales, Kay and Jared brands predominantly in malls with a key demographic being low-to-middle-income engagement ring shoppers, the report adds.
"The Bear Cave further believes the trend of lab-grown diamonds is accelerating quickly, will cause a strong devaluation in both mined and lab-grown diamond prices, and will cause Signet's business to suffer significantly."
A lower price point and ethics concerns over how diamonds are mined could result in the wave of young engagement ring buyers shifting to lab-grown diamonds, the report said.
The Bear Cave cites a rise of posts on social media talking about lab-grown diamonds and their positives as being a potential negative for Signet's future. The report highlights one user's post around the argument for buying an engagement ring that looks better at one-tenth the price and saving thousands of dollars that can be used to spend on a honeymoon or wedding.
Read Also: <a href="https://www.benzinga.com/trading-ideas/short-ideas/24/11/42152301/short-sellers-are-back-flurry-of-big-calls-from-muddy-waters-citron-and-others-raises-questions-why-now">Short Sellers Are Back – Flurry Of Big Calls From Muddy Waters, Citron And Others Raises Questions: Why Now?</a>
What's Next: The growth of lab-grown diamonds could threaten Signet's business model and send prices for diamonds even lower, the report said.
Signet has around $2 billion in inventory on its balance sheet, according to the report. This figure could decline over time and hurt the overall value of the company.
The rise of lab-grown diamonds could result in less frequent purchases of Signet&#8217;s extended service agreements, The Bear Cave said. Service agreements drive high-margin revenue for Signet and are frequently priced as a percentage of the cost of an engagement ring, the short report said, and will decline with the price of engagement rings. 
Signet recently lowered its fourth-quarter revenue guidance from a range of $2.38 billion to $2.46 billion to a new range of $2.32 billion to $2.335 billion. Shares fell in December after the company<a href="https://www.benzinga.com/news/earnings/24/12/42340973/signet-jewelers-stock-tanks-after-dismal-q3-print-guidance-cut"> reported third-quarter</a> revenue and earnings per share that missed analyst estimates. 
SIG Price Action: Signet stock is down 2.19% to $57.63 on Thursday versus a 52-week trading range of $54.44 to $112.06. Signet stock is down 21% over the last five days and down 31% over the last month.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/11/42119918/musk-ramaswamy-should-target-transdigm-in-budget-cuts-short-report-says-target-1-for-doge">Musk, Ramaswamy Should Target TransDigm In Budget Cuts, Short Report Says: &#8216;Target #1&#8217; For D.O.G.E.</a></li>
</ul>
Photo via Shutterstock.

Equities

Short Sellers

Short Ideas

Markets

Trading Ideas

Signet Jewelers Stock No Diamond In The Rough At 52-Week Lows, New Short Report Says 'Business To Suffer Significantly'

Goldman Sachs analyst Bruno Amorim maintains Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) with a Neutral and lowers the price target from $3.1 to $2.7.

AZUL

Goldman Sachs Maintains Neutral on Azul, Lowers Price Target to $2.7

On Thursday, Outlook Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43023003/outlook-therapeutics-announces-complete-twelve-week-efficacy-and-safety-results-of-norse-eight-cli" rel="noreferrer noopener">degeneration (wet AMD) patients</a>.
ONS-5010 demonstrated non-inferiority to Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) / Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Lucentis (ranibizumab) at week 12 in the NORSE EIGHT trial. Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025.
The difference in the mean between ONS-5010 and ranibizumab was -1.009 best corrected visual acuity (BCVA) letters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37893076/why-is-eye-disease-focused-outlook-therapeutics-stock-trading-higher-on-friday" rel="noreferrer noopener">Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?</a>
BCVA measures how well a person can see after wearing corrective lenses, such as glasses or contact lenses.
In the intent-to-treat (ITT) population, NORSE EIGHT demonstrated a mean 5.5 letter improvement in BCVA in the ONS-5010 arm and 6.5 letter improvement in BCVA in the ranibizumab arm.
As previously announced, in the NORSE EIGHT trial, ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 outlined in the special protocol assessment (SPA) with the U.S. <a target="_blank" href="https://www.benzinga.com/24/11/42214804/why-is-eye-disease-focused-outlook-therapeutics-stock-trading-lower-on-wednesday" rel="noreferrer noopener">Food and Drug Administration (FDA)</a>.
However, BCVA data across all study timepoints demonstrated an improvement in vision, increasing over time, and the presence of biologic activity.
Overall, in NORSE EIGHT, ONS-5010 demonstrated mean visual acuity improvements of +3.3 letters at week 4, +4.2 letters at week 8, and +5.5 letters at week 12.
ONS-5010 was generally well-tolerated with overall ocular adverse event rates comparable to ranibizumab.
ONS-5010/LYTENAVA (bevacizumab gamma) has been approved in the European Union and the United Kingdom. Outlook Therapeutics intends to begin launching in Europe in the first half of calendar 2025.
The company also entered into agreements for warrant inducement transactions expected to result in up to $20.4 million in gross proceeds.
The company will use the proceeds to fund its ONS-5010 clinical development programs, the European commercial launch of LYTENAVA, and working capital and general corporate purposes.
Price Action: OTLK stock is down 9.78% at $2.06 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion" target="_blank" rel="noreferrer noopener">Ingevity Explores Strategic Options For Performance Chemicals Segment To Strengthen Portfolio, Projects FY24 Revenue At $1.40 Billion</a></li>
</ul>

Biotech

Financing

Offerings

General

OTLK

RHHBY

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

TD Cowen analyst Bill Katz upgrades Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) from Hold to Buy and raises the price target from $26 to $28.

Upgrades

TD Cowen Upgrades Blue Owl Cap to Buy, Raises Price Target to $28

Raymond James analyst Patrick Tyler Brown maintains Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a Outperform and lowers the price target from $298 to $295.

Raymond James Maintains Outperform on Vulcan Materials, Lowers Price Target to $295

- Extends $5M payables to long-term, including Sound Exchange
- Pays off $2.75M East West Bank line
- Allocates savings to strategic initiatives, including:
- Converting more Tesla subscribers
- Expanding B2B partnerships, including the $25M+ deal announced last week with a Fortune 500 company
- Expanding slate of Original IP
- Enhancing music partnerships
- Monetizing data business utilizing AI
LOS ANGELES, Jan. 16, 2025 (GLOBE NEWSWIRE) -- LiveOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>), an award-winning, creator-first, music, entertainment, and technology platform, today provided a business and financial update.
Robert Ellin, Chairman and CEO, stated, "I'm excited to use our recent cash flow savings to strengthen our balance sheet, expand music partnerships, and grow content globally. By leveraging AI, data analytics, and original programming, we'll drive subscriber growth, unlock new revenue streams, and solidify our leadership in the B2B music space."

LiveOne Extends $5M Payables, Pays $2.75M Debt, Plans On Converting More Tesla Subscribers, Expands B2B Partnerships, Enhances Music & Original IP, Leverages AI For Data Monetization, Plans Global Content Growth

Silexion Therapeutics Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) revealed new preclinical results demonstrating the synergistic efficacy of its SIL-204, in combination with components of first-line chemotherapy <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43014901/silexion-therapeutics-announces-additional-promising-preclinical-data-for-sil-204-demonstrating-im" rel="noreferrer noopener">for pancreatic cancer</a>.
The additional preclinical data show that SIL-204 exhibits significant synergistic activity with 5-fluorouracil and irinotecan — two main components commonly used in pancreatic cancer treatments — when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, the most common mutation in pancreatic cancer.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41123595/silexion-investigational-pancreatic-cancer-treatment-shows-promise-in-animal-studies" rel="noreferrer noopener">Silexion Investigational Pancreatic Cancer Treatment Shows Promise In Animal Studies</a>
Synergistic activity was also observed with the chemotherapeutic agent gemcitabine.
<ul>
<li>Synergistic activity was observed after the&nbsp;confluence of these tumor cell lines,&nbsp;reflecting how SIL-204 may enhance the effects of 5-fluorouracil and irinotecan when used together, as well as that of gemcitabine.&nbsp;</li>
<li>In preclinical models, combining 5-fluorouracil and irinotecan with SIL-204 led to a significant reduction in cancer cell confluence after about three days compared to treatment with the chemotherapy agents alone.&nbsp;</li>
</ul>
Silexion is planning to initiate toxicology studies with SIL-204 within the upcoming months and to advance SIL-204 into Phase 2/3 clinical trials in the first half of 2026, focusing initially on locally advanced pancreatic cancer (LAPC).
In parallel, the company plans to initiate preclinical studies for SIL-204 in colorectal cancer models.
Concurrently, Silexion Therapeutics priced a public offering of 3.7 million shares and warrants to purchase up to 3.7 million shares at a combined price of $1.35 per share and accompanying warrant, with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43018763/silexion-therapeutics-announces-pricing-of-5-0-million-public-offering" rel="noreferrer noopener">gross proceeds of $5 million</a>.
SLXN Price Action: SLXN stock is down 42.96% at 89 cents at publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43026092/bank-of-america-q4-earnings-67-billion-profit-revenue-jumps-15-investment-banking-and-deposit-growth" target="_blank" rel="noreferrer noopener">Bank of America Q4 Earnings: $6.7 Billion Profit, $1.7 Billion In Investment banking fees, Forecasts Higher NII In 2025</a></li>
</ul>
Photo: Romix Image via Shutterstock

SLXN

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

São Paulo-based airline Azul SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) shares are <a href="https://www.benzinga.com/topic/airlines">trading higher on Thursday</a>. 
What Happened: Seaport Research Partners analyst Daniel McKenzie upgraded the stock <a href="https://www.benzinga.com/quote/AZUL/analyst-ratings">from Neutral to Buy</a> and announced a price forecast of $5.00.
In October 2024, the analyst downgraded Azul due to concerns over long-term pricing and a technical pressure stemming from lessors aiming to monetize their equity stakes.
The analyst noted that pricing was not aligning with rising interest expenses, indicating Azul would need to capture a larger market share from GOL and LATAM, a strategy that was deemed unsustainable.
Also, while airlines typically trade at 4-6x EV/EBITDAR, growth, increasing debt, and Brazil&#8217;s historical economic and currency volatility made the analyst cautious in both rating and valuation.
Today, Azul and Abra, the majority investor of Gol and Avianca, intend to <a href="https://www.benzinga.com/pressreleases/25/01/n43018075/azul-and-abra-sign-non-binding-mou-with-intent-to-combine-their-businesses-in-brazil">combine their businesses in Brazil</a>.
The potential economics of the deal, including merger synergies, are compelling and bolster the analyst&#8217;s confidence in long-term revenue growth.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43018900/from-adani-to-nikola-how-hindenburg-research-reshaped-short-selling-before-its-final-bow">From Adani To Nikola: How Hindenburg Research Reshaped Short-Selling Before Its Final Bow</a>
Why It Matters: This is not a typical merger. Both airlines are expected to remain separate.
The analyst&#8217;s revenue projections are enhanced by network optimization, fleet streamlining, better connectivity, stronger domestic presence to support international expansion, and an improved loyalty program expected to boost corporate market share.
Company management has thus far resolved governance and social issues.
The analyst also argues that the size of Brazil&#8217;s traveling population (up to 20 million) supports a two-airline model. 
A merger presents a strong economic case for both airlines and their bondholders, the analyst says. Synergies should fall conservatively in the range of 5.5%-6.5%.
A merger prompts the analyst to establish a $5.00 price forecast. That&#8217;s based on Azul&#8217;s EV trading at 4.5x the 2025 EBITDAR of R$7.3 billion ($1.46 billion).
Price Action: Azul is trading higher by 4.4% at last check Thursday, at $2.26 per share.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43031980/big-banks-continue-to-beat-q4-earnings-financial-etf-takes-breather">Big Banks Continue To Beat Q4 Earnings As Financial ETF Takes A Breather</a></li>
</ul>
Image: Shutterstock

Azul Shares Trade Higher On Heels Of Abra Deal, Analyst Upgrade

<h3>Gainers</h3>
<ul>
<li>Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) shares moved upwards by 11.7% to $6.4 during Thursday's pre-market session. The market value of their outstanding shares is at $141.8 million. </li>
<li>Hour Loop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) shares rose 9.9% to $2.44. The company's market cap stands at $85.7 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) shares rose 8.92% to $1.22. The company's market cap stands at $12.7 million. </li>
<li>Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) shares moved upwards by 8.2% to $13.06. The market value of their outstanding shares is at $1.8 billion. </li>
<li>Yunhong Green CTI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHGJ#NASDAQ">YHGJ</a>) shares increased by 7.92% to $0.6. The company's market cap stands at $15.4 million. </li>
<li>PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) stock increased by 7.35% to $1.75. The company's market cap stands at $186.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares fell 16.4% to $0.62 during Thursday's pre-market session. The market value of their outstanding shares is at $177.4 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) stock declined by 14.53% to $0.34. The market value of their outstanding shares is at $3.3 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) stock declined by 14.05% to $0.04. The market value of their outstanding shares is at $4.0 million. </li>
<li>Vision Marine Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>) shares declined by 12.69% to $1.79. The company's market cap stands at $9.8 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Ambow Education Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) shares decreased by 11.77% to $1.8. The company's market cap stands at $5.1 million. </li>
<li>Polestar Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) stock decreased by 11.48% to $1.08. The company's market cap stands at $2.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMBO

HOUR

LCUT

NWTN

PLBY

PSNY

RIME

TCTM

VMAR

YHGJ

12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

Stephens &amp; Co. analyst Tommy Moll upgrades Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) from Equal-Weight to Overweight and raises the price target from $275 to $350.

Stephens & Co. Upgrades Rockwell Automation to Overweight, Raises Price Target to $350

CORRECTION: Dana ticker Is 'DAN'

WIIM

Dana shares are trading higher after UBS upgraded the stock from Neutral to Buy and increased its price target from $11 to $18.

Wolfe Research analyst Mike Polark downgrades Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) from Peer Perform to Underperform and maintains the price target from $60 to $60.

Downgrades

Wolfe Research Downgrades Edwards Lifesciences to Underperform, Maintains Price Target to $60

Raymond James analyst Patrick Tyler Brown maintains Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) with a Outperform and lowers the price target from $640 to $630.

Raymond James Maintains Outperform on Martin Marietta Materials, Lowers Price Target to $630

High-rolling investors have positioned themselves bearish on FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in FDX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for FedEx. This is not a typical pattern.
The sentiment among these major traders is split, with 33% bullish and 66% bearish. Among all the options we identified, there was one put, amounting to $28,855, and 8 calls, totaling $1,330,530.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $200.0 to $240.0 for FedEx over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for FedEx options trades today is 328.83 with a total volume of 254.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for FedEx's big money trades within a strike price range of $200.0 to $240.0 over the last 30 days.
<h3>FedEx Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737046866_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$58.2</td>
<td>$54.75</td>
<td>$57.0</td>
<td>$220.00</td>
<td>$513.0K</td>
<td align="right">271</td>
<td align="right">90</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$40.9</td>
<td>$40.3</td>
<td>$40.3</td>
<td>$240.00</td>
<td>$362.6K</td>
<td align="right">81</td>
<td align="right">0</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$79.4</td>
<td>$78.5</td>
<td>$78.5</td>
<td>$200.00</td>
<td>$172.7K</td>
<td align="right">225</td>
<td align="right">7</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$37.3</td>
<td>$36.0</td>
<td>$36.0</td>
<td>$240.00</td>
<td>$82.8K</td>
<td align="right">438</td>
<td align="right">23</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$47.75</td>
<td>$45.5</td>
<td>$45.5</td>
<td>$230.00</td>
<td>$68.2K</td>
<td align="right">362</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About FedEx</h3>
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2024, which ended in May, FedEx derived 47% of revenue from its express division, 37% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.
<h3>Present Market Standing of FedEx</h3>
<ul>
<li>Currently trading with a volume of 267,982, the FDX's price is up by 0.01%, now at $276.62. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 63 days.</li>
</ul>
<h3>What The Experts Say On FedEx</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $360.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Loop Capital has elevated its stance to Buy, setting a new price target at $365. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on FedEx with a target price of $368. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on FedEx, which currently sits at a price target of $370. 
&#x2A; An analyst from UBS persists with their Buy rating on FedEx, maintaining a target price of $350. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on FedEx with a target price of $348. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for FedEx with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

FedEx's Options: A Look at What the Big Money is Thinking

Financial giants have made a conspicuous bearish move on BlackRock. Our analysis of options history for BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) revealed 12 unusual trades.
Delving into the details, we found 16% of traders were bullish, while 58% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $631,190, and 6 were calls, valued at $437,557.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $470.0 to $1340.0 for BlackRock over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for BlackRock's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across BlackRock's significant trades, within a strike price range of $470.0 to $1340.0, over the past month.
<h3>BlackRock Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737046860_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLK</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$70.4</td>
<td>$64.6</td>
<td>$67.0</td>
<td>$1020.00</td>
<td>$268.0K</td>
<td align="right">4</td>
<td align="right">40</td>
</tr>
<tr>
<td>BLK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$98.9</td>
<td>$96.0</td>
<td>$98.9</td>
<td>$1000.00</td>
<td>$187.9K</td>
<td align="right">70</td>
<td align="right">20</td>
</tr>
<tr>
<td>BLK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$135.9</td>
<td>$135.9</td>
<td>$135.9</td>
<td>$1100.00</td>
<td>$135.9K</td>
<td align="right">13</td>
<td align="right">10</td>
</tr>
<tr>
<td>BLK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$103.6</td>
<td>$96.7</td>
<td>$103.6</td>
<td>$1100.00</td>
<td>$114.0K</td>
<td align="right">2</td>
<td align="right">21</td>
</tr>
<tr>
<td>BLK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$128.5</td>
<td>$122.0</td>
<td>$128.5</td>
<td>$1040.00</td>
<td>$89.9K</td>
<td align="right">0</td>
<td align="right">8</td>
</tr>
</tbody>
</table>

<h3>About BlackRock</h3>
BlackRock is the largest asset manager in the world, with $11.475 trillion in assets under management at the end of September 2024. Its product mix is fairly diverse, with 55% of managed assets in equity strategies, 26% in fixed income, 9% in multi-asset classes, 7% in money market funds, and 3% in alternatives. Passive strategies account for around two thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which by our calculations account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one third of managed assets coming from investors domiciled outside the US and Canada.
After a thorough review of the options trading surrounding BlackRock, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is BlackRock Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 378,961, with BLK's price down by -1.94%, positioned at $993.48.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 85 days.</li>
</ul>
<h3>Expert Opinions on BlackRock</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $1125.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JP Morgan persists with their Neutral rating on BlackRock, maintaining a target price of $971. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for BlackRock, targeting a price of $1160. 
&#x2A; Maintaining their stance, an analyst from Keefe, Bruyette &amp; Woods continues to hold a Outperform rating for BlackRock, targeting a price of $1160. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on BlackRock, which currently sits at a price target of $1155. 
&#x2A; An analyst from Keefe, Bruyette &amp; Woods persists with their Outperform rating on BlackRock, maintaining a target price of $1180. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for BlackRock with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of BlackRock's Latest Options Trends

Investors with a lot of money to spend have taken a bearish stance on Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with INTU, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Intuit.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 57%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $411,423, and 8 are calls, for a total amount of $311,690.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $590.0 and $800.0 for Intuit, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Intuit's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Intuit's whale activity within a strike price range from $590.0 to $800.0 in the last 30 days. 
<h3>Intuit Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737046855_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.7</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$620.00</td>
<td>$98.8K</td>
<td align="right">506</td>
<td align="right">200</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$12.7</td>
<td>$12.6</td>
<td>$12.6</td>
<td>$590.00</td>
<td>$79.9K</td>
<td align="right">83</td>
<td align="right">191</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.6</td>
<td>$1.4</td>
<td>$2.6</td>
<td>$620.00</td>
<td>$76.7K</td>
<td align="right">193</td>
<td align="right">304</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$12.6</td>
<td>$12.1</td>
<td>$12.5</td>
<td>$590.00</td>
<td>$75.0K</td>
<td align="right">83</td>
<td align="right">251</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$12.2</td>
<td>$12.2</td>
<td>$12.2</td>
<td>$590.00</td>
<td>$62.2K</td>
<td align="right">83</td>
<td align="right">51</td>
</tr>
</tbody>
</table>

<h3>About Intuit</h3>
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of US market share for small-business accounting and do-it-yourself tax-filing software.
After a thorough review of the options trading surrounding Intuit, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Intuit's Current Market Status</h3>
<ul>
<li>Trading volume stands at 781,998, with INTU's price down by 0.0%, positioned at $621.45.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 35 days.</li>
</ul>
<h3>Expert Opinions on Intuit</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $765.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $765. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intuit with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

INTU

Intuit Unusual Options Activity

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy and maintains $36 price target.

OMER

D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

The market kicked off with a notable rally, marking the return of what appears to be a "risk-on" environment.

Maximizing Gains: StoryTrading's Four Pillars Highlight The Best Plays Today

In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on TransMedics Group (TMDX – Research Report), with a price target...

Oppenheimer Sticks to Its Buy Rating for TransMedics Group (TMDX)

TransMedics: A Cash Burn Problem That's Hard To Ignore

Scorpion Capital said in a newly-issued short report that in "20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque healthcare...

TransMedics named as short idea with $0 target by Scorpion Capital

09:17 EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short report Published first on TheFly – the ultimate source for real-time, ...

TransMedics down 10% to $65.39 after Scorpion Capital short report

TransMedics Group drops after Scorpion Capital short call

TransMedics (TMDX) Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion Capital on...

TransMedics says claims made by Scorpion Capital 'have no merit'

Next Century Growth Investors Q4 2024 Commentary

Headwaters Capital Q4 2024 Investor Letter

TransMedics: Misplaced Fear

ADBE

ALHC

AMZN

APPF

ASTS

ATRO

AVAV

AVPT

AXON

BWIN

BYON

CAVA

CBLL

CDNA

CLMB

DXCM

FUBO

GDYN

GWRE

INOD

KIDS

KRUS

KTOS

LNTH

MNDY

MPTI

MPWR

MYRG

NSSC

NVDA

ODFL

PCTY

PEGA

PLTR

PNFP

PYCR

RXST

SAIA

SARO

SIBN

SPSC

TNDM

TOST

TSLA

USAP

VERX

VRRM

VRTX

WDAY

WEAV

WING

XMTR

Press Releases

TransMedics Responds to Inaccurate and Misleading Claims in Recent Short-Seller Report

Rosen Law Firm Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX

Legal

TransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking – Hagens Berman

TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Securities Fraud Investigation with the Schall Law Firm

TransMedics Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

TransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking - Hagens Berman

TMDX Investor News: Rosen Law Firm Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDX

TransMedics Group, Inc. Announcement: If You Have Suffered Losses in TransMedics Group, Inc. (NASDAQ: TMDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NASDAQ: TMDX Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages TransMedics Group, Inc. (NASDAQ: TMDX) Investors with Significant Losses to Contact the Firm

TRANSMEDICS ALERT: Bragar Eagel & Squire, P.C. is Investigating TransMedics Group, Inc. on Behalf of TransMedics Stockholders and Encourages Investors to Contact the Firm

Comments

TransMedics Gr

뉴스

에 대한 최신 뉴스 TransMedics Gr (NASDAQ:TMDX) 주식

월요일, 10월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌